Summary
21 / 100 · Bulios Score
What speaks for it
- It has no debt and holds $7.70M in cash.
What to watch
- Revenue fell by 46% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Is it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 25% a year over 5 years. Over the last 3 years it fell by 46% a year.
Growth in detailDoes it make money?
Over the last 12 months it made a loss of $316.1M.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 0.07%
You receive $0.01 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 5
- Hold 1
- Sell 0
No analyst has published a price target.
83% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.